et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2021.02.029 (Peer Reviewed)
Retrospective 29 remdesivir patients and 113 controls, not finding a significant difference in nasopharyngeal viral load or hospitalization time. Hospitalization time was lower with treatment, with a larger reduction for non-intubated patients, although not statistically significant in both cases.
Goldberg et al., 3/9/2021, retrospective, Israel, Middle East, peer-reviewed, 7 authors.
hospitalization time, 9.2% lower, relative time 0.91, p = 0.77, treatment 29, control 113.
hospitalization time, 21.8% lower, relative time 0.78, p = 0.30, non-intubated patients only.
risk of no virological cure, 0.1% lower, RR 1.00, p = 0.98, treatment 29, control 113, relative change in Ct values.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.